MDABY Stock UPDATES Meda Ab (MDABY) 13.4200 09/01/2014 17:36

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Meda Ab (MDABY) 13.4200 $MDABY

Meda posts net profit of SEK503m in January to June 2014
M2 - Thu Aug 14, 4:26AM CDT
Specialty pharmaceutical company Meda AB (STO:MEDAA) on Wednesday reported profit after tax of SEK503m, or EPS of SEK1.66, for the six month period of January 2014 to June 2014.

Fibromyalgia - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vjrklg/fibromyalgia) has announced the addition of the "Fibromyalgia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fibromyalgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibromyalgia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fibromyalgia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fibromyalgia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Eli Lilly and Company - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Meda AB - Pfizer Inc. - Collegium Pharmaceutical, Inc. - Theravance, Inc. - e-Therapeutics plc - Concert Pharmaceuticals, Inc. - SWITCH Biotech LLC - EirGen Pharma Ltd. - Tonix Pharmaceuticals Holding Corp. For more information visit http://www.researchandmarkets.com/research/vj...bromyalgia

Global Non-melanoma Skin Cancer Market 2014-2018: Market Size and CAGR
M2 - Thu Jun 12, 9:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/slg7cn/global) has announced the addition of the "Global Non-melanoma Skin Cancer Market 2014-2018" report to their offering. The analysts forecast the Global Non-melanoma Skin Cancer market to grow at a CAGR of 27.93 percent over the period 2013-2018. Covered in this Report This report covers the present scenario and the growth prospects of the Global Non-melanoma Skin Cancer market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the following segments: - Chemotherapy, which includes drugs used in the treatment of SCC, BCC, and actinic keratosis - Non-invasive Treatments, which include PDT, radiotherapy, cryotherapy, and laser therapy Key Vendors - Elekta AB - F. Hoffmann-la Roche Ltd. - iCAD Inc. - Meda AB - Valeant Pharmaceuticals Inc. - Varian Medical Systems Inc. Commenting on the report, an analyst from the team said: A current trend witnessed in the Global Non-melanoma Skin Cancer market is the use of combination therapies for the treatment of non-melanoma skin cancer. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapies help in the complete removal of tumors and destruction of cancerous cells. For instance, radiation therapy may be used in combination with other therapies (chemotherapy and surgery) to treat aggressive or recurrent non-melanoma skin cancer. Patients that are non-reactive may react to combination therapy with 0.5 percent tretinoin cream with 5-FU cream. For more information visit http://www.researchandmarkets.com/research/slg7cn/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Meda AB (publ) Notice of Annual General Meeting 2014
Business Wire - Wed Apr 02, 5:30AM CDT
Notice is hereby given that the Annual General Meeting (AGM) of Meda AB (STO:MEDAA), corporate ID 556427-2812, will be held at 5.00 PM on Wednesday, May 7, 2014 at Meda's headquarters at Pipers vag 2A, Solna, Sweden. Registration starts at 4.00 PM.

MEDA: Nomination Committee's Proposal for Composition of the Board
Business Wire - Fri Mar 28, 4:04AM CDT
Regulatory News:

MEDA: Invitation to Teleconference for Analysts, Investors and Journalists
Business Wire - Tue Feb 11, 7:48AM CST
Meda AB (STO:MEDAA):

Meda announces organisational changes
M2 - Mon Aug 05, 3:20AM CDT
Specialty pharma company Meda AB (STO:MEDAA.ST) announced today that Jorg-Thomas Dierks, its chief operating officer (COO), will now have expanded responsibilities which will include Meda's US operations.

MEDA posts net profit of SEK400m in H1 2013
M2 - Fri Aug 02, 10:07AM CDT
Speciality pharmaceutical company MEDA AB (STO:MEDAA) today reported interim profit after tax of SEK400m, or SEK1.34 per share, for the period January 2013 to June 2013.

Actinic Keratosis - Pipeline Review, H2 2012
M2 - Fri Aug 02, 6:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2gp3d/actinic_keratosis) has announced the addition of the "Actinic Keratosis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for actinic keratosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for actinic keratosis. The information is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for actinic keratosis. - A review of the actinic keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the actinic keratosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for actinic keratosis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding actinic keratosis pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Actinic Keratosis Overview Therapeutics Development An Overview of Pipeline Products for Actinic Keratosis Companies Involved in Actinic Keratosis Therapeutics Development Actinic Keratosis - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Almirall, S.A - Birken GmbH - Celtic Pharmaceutical Holdings L.P - Clinuvel Pharmaceuticals Limited - FunZyme BioTechnologies S.A - GliaMed, Inc - Meda AB - MediQuest Therapeutics, Inc - Moberg Derma AB - NexMed, Inc - Quest PharmaTech Inc - Telormedix SA For more information visit http://www.researchandmarkets.com/research/s2..._keratosis

Meda AB (publ) AGM bulletin
Business Wire - Tue May 07, 12:31PM CDT
Regulatory News:

MEDA: Interim Report, January-March 2013
Business Wire - Tue May 07, 1:31AM CDT
Regulatory News:

Warner Chilcott Announces Changes to Board of Directors
GlobeNewswire - Thu May 02, 3:15PM CDT
Warner Chilcott plc (Nasdaq:WCRX) today announced that its Board of Directors has voted unanimously to appoint Paul Herendeen, the Company's Executive Vice President and Chief Financial Officer, to the Company's Board effective as of May 2, 2013. Mr. Herendeen will continue to serve as Executive Vice President and Chief Financial Officer of the Company.

FIN® Branding Group Taps Former Burger King & Nestle Exec To Lead Marketing Efforts
PR Newswire - Tue Apr 30, 12:16PM CDT
Leading electronic cigarette company FIN Branding Group has appointed Joana Martins its vice president of marketing. Martins brings more than 14 years of consumer-focused branding to her new role, including stints at Burger King Brands and Nestle USA. At FIN, Martins will develop and execute marketing and communication strategies to position FIN's industry leadership.

Rhinitis - Pipeline Review, H1 2013
M2 - Mon Apr 15, 5:21AM CDT
Research and Markets has announced the addition of the "Rhinitis - Pipeline Review, H1 2013" report to their offering. 'Rhinitis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rhinitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhinitis. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Rhinitis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Rhinitis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strateg




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 61

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 53

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 51

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Jalisco’s Culinary Push Puts Tourism Strategy in Focus

Updated Category News Views 50

A destination sells itself twice: first with a memorable meal, then with a reason to come back. Jalisco’s stated effort to connect the world’s cuisines through The 50 Best Gastronomic Experiences belongs in that second category. It is not merely restaurant chatter. It reads as part of a broader attempt to make the state’s tourism offering feel deeper, more varied...

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 67

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 22

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Holland America Tests Asia Demand With Eurodam Debut

Updated Category News Views 128

Cherry blossoms are not normally the sort of thing that gets my investor blood moving, but a ship deployment decision does. Holland America Line is sending Eurodam into Asia for its first season there from September 2028 through May 2029, and it is plainly trying to sell more than transportation between postcard ports. The pitch is time: five new ports, 14 ports with...

Continue Reading

Top 5 Most Recently Viewed Articles

InsCorp, Inc. Experiences Significant Growth Impact in 2025

Updated Category News Views 229

InsCorp, Inc. Sees Improved Financial Metrics in 2025 InsCorp, Inc. (OTCQX: IBTN) has announced results for the second quarter of 2025, demonstrating a noticeable upward trend in earnings per share (EPS) at $0.73, an increase from $0.57 in the prior quarter and $0.63 over the same period last year. Jim Rieniets, the President and CEO of INSBANK, expressed optimism about...

Continue Reading
Revance Celebrates National Sunscreen Day with Times Square Billboard

Updated Category News Views 223

Revance Celebrates National Sunscreen Day with a Bold Message Revance is thrilled to commemorate National Sunscreen Day with a vibrant digital billboard in Times Square. This event not only marks a celebration of Blue Lizard® Australian Sunscreen but also highlights the importance of sun safety as the summer season approaches. Blue Lizard is recognized as the leading...

Continue Reading
Exploring Noah Holdings' Strategic Vision for Global Growth

Updated Category News Views 523

Noah's Global Expansion and Innovative Services Noah Holdings has actively pushed the envelope in providing innovative financial services tailored to meet the diverse wealth management requirements of its clients. This year marks a significant chapter in their journey toward international expansion, where they are introducing groundbreaking solutions along with targeted...

Continue Reading
Streamline Your Taxes: Harness QuickBooks Reports Now

Updated Category News Views 21

QuickBooks: Not Just for Bookkeeping Anymore Taxes can be a pain, but if you're rocking QuickBooks, there's a silver lining. Karen Eberhart Metcalfe, the accounting whiz from Bolingbrook, IL, assures us that this tool isn't merely for ticking boxes in bookkeeping; it's your ace for navigating tax season with less sweat and more precision. When you’ve got those reports...

Continue Reading
Vistra's Options Trading Insights: What Big Investors Indicate

Updated Category News Views 177

Understanding Vistra's Options Trading Landscape Investors are closely observing the options trading activity for Vistra (NYSE: VST) as it indicates a notable bearish sentiment among significant traders. Retail traders would benefit from being aware of these trends. Current Market Sentiment Recent data revealed on options trading history highlights that a recognizable...

Continue Reading